AEON Biopharma, Inc. (AEON)
| Market Cap | 12.47M +13.9% |
| Revenue (ttm) | n/a |
| Net Income | -54.62M |
| EPS | -1.89 |
| Shares Out | 49.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 128,987 |
| Open | 0.2400 |
| Previous Close | 0.2400 |
| Day's Range | 0.2400 - 0.2549 |
| 52-Week Range | 0.1772 - 1.4500 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 1.82 (+628.0%) |
| Est. Earnings | Nov 13, 2026 |
About AEON
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for AEON stock is "Strong Buy." The 12-month stock price target is $1.82, which is an increase of 628.00% from the latest price.
News
AEON Biopharma Proxy statement: Proxy filing
AEON Biopharma filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
AEON Biopharma Slides: Corporate presentation
AEON Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on October 22, 2026.
AEON Biopharma Proxy statement: Proxy filing
AEON Biopharma filed a proxy statement on October 13, 2026, providing details for shareholder voting and corporate governance matters.
Aeon Biopharma price target raised to $2 from $1 at Lake Street
Lake Street raised the firm’s price target on Aeon Biopharma (AEON) to $2 from $1 and keeps a Buy rating on the shares after the company announced the outcome of…
Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450
AEON Biopharma (AEON) announced receipt of the official minutes from its Biosimilar Biological Product Development Type 2b meeting held with the U.S. Food and Drug Administration regarding ABP-450’s d...
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submi...
Aeon Biopharma announces results from ABP-450 pilot forced degradation study
Aeon Biopharma (AEON) announced results from a pilot forced degradation study comparing ABP-450 to Botox under thermal and oxidative stress conditions. Under thermal stress, both ABP-450 and Botox los...
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®
ABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytic...
Aeon Biopharma initiated with a Buy at Laidlaw
Laidlaw initiated coverage of Aeon Biopharma (AEON) with a Buy rating and $1.80 price target Aeon is a mid-development stage specialty pharma company focused on developing ABP-450 as a potential…
AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference
ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (on...
Aeon Biopharma designates Paul Lee as acting chief regulatory officer
Aeon Biopharma (AEON) announced the designation of Paul Lee as the company’s acting chief regulatory officer, through Clintrex. Lee and Clintrex currently advise Aeon on the regulatory and clinical de...
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
- Former Deputy Director of the FDA's Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory...
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed
Aeon Biopharma price target lowered to $1.20 from $5 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Aeon Biopharma (AEON) to $1.20 from $5 and keeps a Buy rating on the shares. ABP-450’s biosimilar development remains…
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program
AEON Biopharma Earnings release: Q2 2026
AEON Biopharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
AEON Biopharma Quarterly report: Q2 2026
AEON Biopharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
AEON Biopharma Slides: Corporate presentation
AEON Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (on...
Lake Street starts Aeon Biopharma at Buy on potential of Botox competitor
As previously reported, Lake Street initiated coverage of Aeon Biopharma (AEON) with a Buy rating and $1 price target Aeon is developing a biosimilar that has the potential to be…
Aeon Biopharma initiated with a Buy at Lake Street
Lake Street initiated coverage of Aeon Biopharma (AEON) with a Buy rating and $1 price target
Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards
VICTORIA, Seychelles, July 27, 2026 (GLOBE NEWSWIRE) -- Bitget , the world's largest Universal Exchange (UEX), announced the addition of AEON (AEON) to Bitget Launchpool and spot market. Spot trading ...
Aeon announces pricing of upsized $13.75M public offering
Aeon Biopharma (AEON) announced the pricing of its underwritten public offering to raise up to approximately $43.3M in gross proceeds based on the approximately $13.75M in expected gross proceeds from...
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering $13.75 milli...
AEON Biopharma Registration statement: Registration filing
AEON Biopharma filed a registration statement on July 9, 2026, providing details about a securities offering with the SEC.